Single-dose gadobutrol in comparison with single-dose gadobenate dimeglumine for magnetic resonance imaging of chronic myocardial infarction at 3 T

Investigative Radiology

Volumn 49, Issue 11, 2014, Pages 728-734

  Wildgruber, Moritz ^a   Stadlbauer, Thomas ^a   Rasper, Michael ^a   Hapfelmeier, Alexander ^a   Zelger, Otto ^b   Eckstein, Hans Henning ^a   Halle, Martin ^b   Rummeny, Ernst J ^a   Huber, Armin M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Contrast agent; Late gadolinium enhancement; Magnetic resonance imaging; Myocardial infarction

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; CONTRAST MEDIUM; GADOLINIUM PENTETATE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTRAST TO NOISE RATIO; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIGNAL NOISE RATIO; SINGLE DRUG DOSE; COMPARATIVE STUDY; DIAGNOSTIC USE; IMAGE ENHANCEMENT; MYOCARDIAL INFARCTION; PATHOLOGY; PROCEDURES; REPRODUCIBILITY;

AGED; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SIGNAL-TO-NOISE RATIO;

EID: 84925940933     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000076     Document Type: Article

References (30)

1. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm-paradoxic or predictable? Circulation. 1993;88:296-306.
2. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-1453.
3. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006;113:2733-2743.
4. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215-223.
5. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.
6. Goetti R, Feuchtner G, Stolzmann P, et al. Delayed enhancement imaging of myocardial viability: low-dose high-pitch CT versus MRI. Eur Radiol. 2011;21:2091-2099.
7. Meyer C, Strach K, Thomas D, et al. High-resolution myocardial stress perfusion at 3 T in patients with suspected coronary artery disease. Eur Radiol. 2008;18:226-233.
8. Peel SA, Morton G, Chiribiri A, et al. Dual inversion-recovery MR imaging sequence for reduced blood signal on late gadolinium-enhanced images of myocardial scar. Radiology. 2012;264:242-249.
9. Durmus T, Schilling R, Doeblin P, et al. Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine. Invest Radiol. 2012;47:183-188.
10. Wagner M, Schilling R, Doeblin P, et al. Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison of gadobutrol and gadoterate meglumine. Eur Radiol. 2013;23:108-114.
11. Lonborg J, Vejlstrup N, Mathiasen AB, et al. Myocardial area at risk and salvage measured by T2-weighted cardiovascular magnetic resonance: reproducibility and comparison of two T2-weighted protocols. J Cardiovasc Magn Reson. 2011;13:50.
12. Pujadas S, Vidal-Perez R, Hidalgo A, et al. Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study. Eur J Radiol. 2010;75:e88-e91.
13. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 tesla. Invest Radiol. 2006;41:213-221.
14. Secchi F, Di Leo G, Papini GD, et al. Optimizing dose and administration regimen of a high-relaxivity contrast agent for myocardial MRI late gadolinium enhancement. Eur J Radiol. 2011;80:96-102.
15. Kellman P, Arai AE, McVeigh ER, et al. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med. 2002;47:372-383.
16. Huber AM, Schoenberg SO, Hayes C, et al. Phase-sensitive inversion-recovery MR imaging in the detection of myocardial infarction. Radiology. 2005;237:854-860.
17. Wildgruber M, Settles M, Kosanke K, et al. Evaluation of phase-sensitive versus magnitude reconstructed inversion recovery imaging for the assessment of myocardial infarction in mice with a clinical magnetic resonance scanner. J Magn Reson Imaging. 2012;36:1372-1382.
18. Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J Magn Reson Imaging. 2007;26:1190-1197.
19. Masoudi FA, Plomondon ME, Magid DJ, et al. Renal insufficiency and mortality from acute coronary syndromes. Am Heart J. 2004;147:623-629.
20. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43:817-828.
21. Rofsky NM, Sherry AD, Lenkinski RE. Nephrogenic systemic fibrosis: a chemical perspective. Radiology. 2008;247:608-612.
22. Altun E, Semelka RC, Cakit C. Nephrogenic systemic fibrosis and management of high-risk patients. Acad Radiol. 2009;16:897-905.
23. Reiter T, Ritter O, Prince MR, et al. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:31.
24. Sandstede JJ, Beer M, Lipke C, et al. Time course of contrast enhancement patterns after Gd-BOPTA in correlation to myocardial infarction and viability: a feasibility study. J Magn Reson Imaging. 2001;14:789-794.
25. Balci NC, Inan N, Anik Y, et al. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging. Acad Radiol. 2006;13:833-839.
26. Bauner KU, Reiser MF, Huber AM. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine. Invest Radiol. 2009;44:95-104.
27. Tumkosit M, Puntawangkoon C, Morgan TM, et al. Left ventricular infarct size assessed with 0.1 mmol/kg of gadobenate dimeglumine correlates with that assessed with 0.2 mmol/kg of gadopentetate dimeglumine. J Comput Assist Tomogr. 2009;33:328-333.
28. Klein C, Gebker R, Kokocinski T, et al. Combined magnetic resonance coronary artery imaging, myocardial perfusion and late gadolinium enhancement in patients with suspected coronary artery disease. J Cardiovasc Magn Reson. 2008;10:45.
29. Schlosser T, Hunold P, Herborn CU, et al. Myocardial infarct: depiction with contrast-enhanced MR imaging-comparison of gadopentetate and gadobenate. Radiology. 2005;236:1041-1046.
30. Kawel N, Nacif M, Zavodni A, et al. Tl mapping of the myocardium: intraindividual assessment of post-contrast Tl time evolution and extracellular volume fraction at 3 T for Gd-DTPA and Gd-BOPTA. J Cardiovasc Magn Reson. 2012;14:26.